EU’s Biotech Act Draft Lacks ‘Competition-Driven’ Biosimilar Policies

The Second Part Of The Act Is Expected In 2026

 
• By Urtė Fultinavičiūtė
  
A person standing on a question mark
EU's biotech vision lacks the incentives to stay competitive (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Pink Sheet